These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24880619)

  • 41. Efficacy of combined orbital radiation and systemic steroids in the management of Graves' orbitopathy.
    Kim JW; Han SH; Son BJ; Rim TH; Keum KC; Yoon JS
    Graefes Arch Clin Exp Ophthalmol; 2016 May; 254(5):991-8. PubMed ID: 26876240
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome.
    Ravani P; Ponticelli A; Siciliano C; Fornoni A; Magnasco A; Sica F; Bodria M; Caridi G; Wei C; Belingheri M; Ghio L; Merscher-Gomez S; Edefonti A; Pasini A; Montini G; Murtas C; Wang X; Muruve D; Vaglio A; Martorana D; Pani A; Scolari F; Reiser J; Ghiggeri GM
    Kidney Int; 2013 Nov; 84(5):1025-33. PubMed ID: 23739238
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre.
    Besada E; Koldingsnes W; Nossent JC
    Rheumatology (Oxford); 2013 Nov; 52(11):2041-7. PubMed ID: 23934313
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of rituximab trials on the treatment of ANCA-associated vasculitis.
    Alberici F; Jayne DR
    Nephrol Dial Transplant; 2014 Jun; 29(6):1151-9. PubMed ID: 24126571
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potential utility of rituximab for Graves' orbitopathy.
    Salvi M; Vannucchi G; Beck-Peccoz P
    J Clin Endocrinol Metab; 2013 Nov; 98(11):4291-9. PubMed ID: 24009135
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients.
    Calich AL; Puéchal X; Pugnet G; London J; Terrier B; Charles P; Mouthon L; Guillevin L;
    J Autoimmun; 2014 May; 50():135-41. PubMed ID: 24703438
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early response to intravenous glucocorticoids for severe thyroid-associated ophthalmopathy predicts treatment outcome.
    Hart RH; Kendall-Taylor P; Crombie A; Perros P
    J Ocul Pharmacol Ther; 2005 Aug; 21(4):328-36. PubMed ID: 16117697
    [TBL] [Abstract][Full Text] [Related]  

  • 48. VARIABLES AFFECTING THE LONG-TERM OUTCOME OF GRAVES ORBITOPATHY FOLLOWING HIGH-DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPY.
    Leo M; Mautone T; Ionni I; Profilo MA; Sabini E; Menconi F; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
    Endocr Pract; 2016 Oct; 22(10):1177-1186. PubMed ID: 27732097
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections.
    Savino G; Battendieri R; Gari M; Caputo CG; Laurenti L; Blasi MA
    J Cancer Res Clin Oncol; 2013 Jul; 139(7):1251-5. PubMed ID: 23625184
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use and monitoring of low dose rituximab in myasthenia gravis.
    Blum S; Gillis D; Brown H; Boyle R; Henderson R; Heyworth-Smith D; Hogan P; Kubler P; Lander C; Limberg N; Pillans P; Prain K; Staples C; Walsh M; McCombe P; Wong R
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):659-63. PubMed ID: 21071753
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature.
    Kong WY; Swaminathan R; Irish A
    Int Urol Nephrol; 2013 Jun; 45(3):795-802. PubMed ID: 22798030
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Experience with rituximab treatment (monoclonal antibodies to B-lymphocyte CD20 receptors) of Wegener's granulomatosis patients with renal impairment].
    Novikov PI; Krivosheev OG; Semenkova EN
    Ter Arkh; 2011; 83(11):70-6. PubMed ID: 22312891
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.
    Williams ME; Densmore JJ; Pawluczkowycz AW; Beum PV; Kennedy AD; Lindorfer MA; Hamil SH; Eggleton JC; Taylor RP
    J Immunol; 2006 Nov; 177(10):7435-43. PubMed ID: 17082663
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study.
    Campochiaro C; De Luca G; Lazzaroni MG; Zanatta E; Bosello SL; De Santis M; Cariddi A; Bruni C; Selmi C; Gremese E; Matucci-Cerinic M; Doria A; Airò P; Dagna L
    Rheumatology (Oxford); 2020 Dec; 59(12):3731-3736. PubMed ID: 32413118
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enduring remission of active and sight-threatening Graves' orbitopathy with rituximab: report of two cases.
    Adamidou F; Anagnostis P; Boboridis K; Manani C; Georgiou T; Veneti S; Kita M
    Endocr J; 2018 Sep; 65(9):963-967. PubMed ID: 29937466
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
    Woo YJ; Jang SY; Lim TH; Yoon JS
    Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.
    Andersson H; Sem M; Lund MB; Aaløkken TM; Günther A; Walle-Hansen R; Garen T; Molberg Ø
    Rheumatology (Oxford); 2015 Aug; 54(8):1420-8. PubMed ID: 25740830
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates.
    Salvi M; Vannucchi G; Campi I; Currò N; Simonetta S; Covelli D; Pignataro L; Guastella C; Rossi S; Bonara P; Dazzi D; Ratiglia R; Beck-Peccoz P
    Clin Immunol; 2009 May; 131(2):360-5. PubMed ID: 19195932
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register.
    Sebastiani M; Anelli MG; Atzeni F; Bazzani C; Farina I; Fedele AL; Favalli EG; Fineschi I; Cino N; Dal Forno I; Gasparini S; Cassarà E; Giardina R; Bruschi E; Addimanda O; Cassone G; Lopriore S; Sarzi-Puttini P; Filippini M; Pignatti F; Gremese E; Biggioggero M; Manganelli S; Amato G; Caimmi C; Salaffi F; Iannone F; Ferri C; Sandri G; Lapadula G; Gorla R; Govoni M; Ferraccioli G; Marchesoni A; Galeazzi M; Foti R; Carletto A; Cantini F; Triolo G; Epis OM; Salvarani C;
    Joint Bone Spine; 2014 Dec; 81(6):508-12. PubMed ID: 25082646
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Efficacy and safety of low-dose rituximab combined with different dosage of glucocorticoids for immune thrombocytopenia].
    Xing WW; Li ZY; Yan ZL; Liu KG; Li N; Cao J; Pan XY; He XP; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):409-12. PubMed ID: 23688751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.